Bischloroanthrabenzoxocinone ((-)BABX)

Bischloroanthrabenzoxocinone ((-)BABX) is a selective inhibitor of Type II fatty acid synthesis (FASII). BABX showed IC50 values of 11.4 and 35.3ug/ml in the S. aureus and E. coli FASII assays, respectively, with comparable antibacterial activities. Type II fatty acid synthesis (FASII) is essential to bacterial cell viability and is a promising target for the development of novel antibiotics. More recently, BABX has been shown to inhibit agonist binding Liver X receptors (LXR). The receptors regulate the expression of the ABCA1 gene, which mediates the efflux of cholesterol from cells.

Small volumes of Bischloroanthrabenzoxocinone biochemical vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS6045426 is a biochemical targeting Bischloroanthrabenzoxocinone. Also known as Bischloroanthrabenzoxocinone ((-)BABX). Host: Bischloroanthrabenzoxocinone.